MedWorm: Non-Hodgkin’s Lymphoma

MedWorm.com provides a medical RSS filtering service. Over 5500 RSS medical sources are combined and output via different filters. This feed contains the latest headlines from journals and sites in the Non-Hodgkin’s Lymphoma category.

MedWorm: Non-Hodgkin's Lymphoma
MedWorm.com provides a medical RSS filtering service. Over 6000 RSS medical sources are combined and output via different filters. This feed contains the latest headlines from journals and sites in the Non-Hodgkin's Lymphoma category.

Hormonal and Sex Impact on the Epidemiology of Canine Lymphoma
This study examines the influence of sex on lymphoma risk in a relevant large animal model. Records for dogs in the Veterinary Medical Database were analyzed from 1964 to 2002. Risk ratios were calculated to evaluate associations between sex, neutering status, and lymphoma occurrence. A total of 14,573 cases and 1,157,342 controls were identified. Intact females had a significantly lower risk of developing lymphoma, Odds Ratio 0.69 (0.63–0.74) with a P<.001. We conclude that there is a sex effect on NHL risk in dogs similar to humans. We hypothesize that the hormone levels of intact females lower the risk of NHL. The possibility of a protective role of endogenous estrogens in the etiology of NHL should be investigated. (Source: Journal of Cancer Epidemiology)

Seaweed extract may hold promise for non-Hodgkin's lymphoma treatment
Seaweed extract may eventually emerge as a lymphoma treatment, according to laboratory research. Seaweeds containing fucoidan, a sulfated polysaccharide similar to heparin in chemical structure, have been reported to have anti-tumor activity in mice and some cell lines. (Source: ScienceDaily Headlines)
Review of radiolabelled immunotherapy (90Y ibritumomab tiuxetan - Zevalin® or 131I tositumomab - Bexxar®) as either consolidation therapy after remission induction in previously untreated patients or in patients with relapsed/refractory follicular lymphom
Source: No information given Area: Evidence > Drug Class Focused Reviews This LCNDG review acts as an update to the review published in 2004 (appendix 3) Lymphomas are cancers of the lymphatic system and non-Hodgkin's lymphomas are a heterogeneous group, which vary considerably in their prognosis and management. The majority of non-Hodgkin's lymphomas (80-85%) derive from the B-cell lymphocytes, the rest originate from T-cells or undifferentiated cells. Follicular lymphoma is a common histological type of NHL, originating from B-lymphocytes.  Both 131I tositumomab (Bexxar®) and 90Y ibritumomab tiuxetan (Zevalin®) are murine monoclonal antibodies directed against the CD20 antigen expressed on the surface of normal and malignant B-lymphocytes. Radiolabelled ibritumomab is license...
Epidemiology and outcome of Rhodotorula infection in haematological patients
Rhodotorula spp. are emergent opportunistic pathogens, particularly in haematological patients. However, no systematic review of this infection has been undertaken in this high-risk patient group. The aim of this study was to review all reported cases of Rhodotorula infection to determine the epidemiology and outcome of this infection in this high-risk population. The 29 reported cases were fungaemias. The most common underlying haematological disorder was the presence of acute leukaemia (65.5%). Rhodotorula mucilaginosa was the species found more frequently (79.3%). Most cases (58.6%) had several risk factors ([ge]3) simultaneously. The most common predisposing factors were the presence of central venous catheter (CVC, 100%) and neutropenia (62.1%). A substantial number of patients (81.5%...
Psoriasis Is Associated With an Increased Risk of Cancer
Psoriasis is associated with a significantly greater risk of malignancy, including skin and prostate cancer and non-Hodgkin's lymphoma, according to new research presented here at the 68th annual meeting of the American Academy of Dermatology (AAD 2010). Reuters Health Information (Source: Medscape Hematology-Oncology Headlines)
Seaweed Extract May Hold Promise For Non-Hodgkin's Lymphoma Treatment
Seaweed extract may eventually emerge as a lymphoma treatment, according to laboratory research presented at the second AACR Dead Sea International Conference on Advances in Cancer Research: From the Laboratory to the Clinic, held here March 7-10, 2010... (Source: Lymphoma / Leukemia News From Medical News Today)
Seaweed Extract May Hold Promise For Non-Hodgkin's Lymphoma Treatment
Seaweed extract may eventually emerge as a lymphoma treatment, according to laboratory research presented at the second AACR Dead Sea International Conference on Advances in Cancer Research: From the Laboratory to the Clinic, held here March 7-10, 2010. Lymphoma is a cancer of the immune system and is classified into Hodgkin's and non-Hodgkin's types, which are then further classified into B-cell and T-cell groups. "Some forms of B-cell lymphoma are especially resistant to standard treatment and thus new therapies are needed," said Mohammad Irhimeh, Ph.D... (Source: Health News from Medical News Today)
Surgical treatment of primary tracheobronchial malignant tumors
Conclusion  Surgical resection is the most effective treatment for primary tracheobronchial malignant tumors. The selection of operation modes should be individualized according to patients’ condition. Both complete resection and safety should be taken into consideration simultaneously. Content Type Journal ArticleDOI 10.1007/s10330-009-0182-8Authors Hailong Wang, Guilin Medical College Department of Cardiothoracic Surgery, Affiliated Hospital Guilin 541001 ChinaZhenzong Du, Guilin Medical College Department of Cardiothoracic Surgery, Affiliated Hospital Guilin 541001 ChinaHua Ren, Peking Union Medical College Department of Cardiothoracic Surgery, Peking Union Medical College Hospital Beijing 100730 ChinaChaoji Zhang, Peking Union Medical College Department of Card...
NK/T cell non-Hodgkin lymphoma in a HIV-positive patient
Abstract  NK/T lymphomas have rarely been reported in HIV/AIDS patients. Here we report a case of a 37-year-old woman, with AIDS and a recent diagnosis of Kaposi sarcoma in a mesenteric lymph node, who presented with extra-ocular nerve palsies and gastrointestinal bleeding. A small intestine resection specimen revealed an extra-nodal NK/T cell lymphoma, nasal type. The unique presentation of this rare and aggressive lymphoma in the setting of AIDS and Kaposi sarcoma underscores the importance of maintaining a broad differential diagnosis when evaluating a malignant neoplasm from a HIV-positive patient. Content Type Journal ArticleCategory Case ReportDOI 10.1007/s12308-010-0057-5Authors Nicole C. Panarelli, Weill Cornell Medical College Department of Pathology and Labor...
Non-Hodgkins Lymphoma in the Elderly
(Source: Drugs)
Risk of non-Hodgkin lymphoma and nitrate and nitrite from the diet in Connecticut women
Abstract  It has been estimated that 65,980 individuals were diagnosed with non-Hodgkin lymphoma (NHL) and 19,500 died from NHL in the United States in 2009. Although established risk factors such as immunodeficiency and viral infections may be responsible for a portion of the cases, the majority of NHL cases remain unexplained. Dietary nitrate and nitrite intake are exposures of particular interest for NHL risk as they are precursors in the endogenous formation of N-nitroso compounds, which cause lymphomas in animal studies. We investigated NHL risk overall and by histologic type in relation to dietary nitrate and nitrite intake in a population-based case–control study of 1,304 women in Connecticut. Nitrate and nitrite intake were assessed using a 120-item food frequency...
Seaweed extract may hold promise for non-Hodgkin's lymphoma treatment
(American Association for Cancer Research) Seaweed extract may eventually emerge as a lymphoma treatment, according to laboratory research presented at the second AACR Dead Sea International Conference on Advances in Cancer Research. (Source: EurekAlert! - Cancer)
Cutaneous intravascular anaplastic large cell lymphoma
Intravascular lymphoma (IL) is a rare variant of non-Hodgkin lymphoma with a predilection for skin. Most reported cases are large B cell lymphomas. Intravascular anaplastic large cell lymphoma (IALCL) is extremely rare. Retrospective analysis of a case of cutaneous IALCL was performed. Hematoxylin and eosin stained sections and immunohistochemical staining results were analyzed. The patient was a 47-year-old woman who had developed multiple erythematous patches and plaques on her back. The lesions responded well to CHOP (cyclophosphamide, hydroxydoxorubicin, oncovin, prednisone) chemotherapy, but relapsed shortly after therapy. The patient was surviving with the disease for eight years but was ultimately lost to follow up. Histopathologically, the neoplasm evolved from IL to extravascular ...
Anti-CD22 Immunotoxin RFB4(dsFv)-PE38 (BL22) for CD22-Positive Hematologic Malignancies of Childhood: Preclinical Studies and Phase I Clinical Trial.
CONCLUSIONS: CD22 represents an excellent target and anti-CD22 immunotoxins offer therapeutic promise in B-lineage hematologic malignancies of childhood. Clin Cancer Res; 16(6); 1894-903. PMID: 20215554 [PubMed - as supplied by publisher] (Source: Clinical Cancer Research)
FDA Sets March 22 For ODAC Meeting To Review CTI's New Drug Application For Pixantrone
Cell Therapeutics, Inc. ("CTI") (Nasdaq and MTA: CTIC) announced that the U.S. Food and Drug Administration's ("FDA") Oncologic Drugs Advisory Committee ("ODAC") will review CTI's New Drug Application ("NDA") for pixantrone for the treatment of relapsed/refractory aggressive non-Hodgkin's lymphoma ("NHL") on March 22, 2010. The meeting was to take place on February 10, 2010, but the FDA postponed the meeting because of severe weather conditions in the Washington, D.C. area... (Source: Health News from Medical News Today)
FDA Sets March 22 For ODAC Meeting To Review CTI's New Drug Application For Pixantrone
Cell Therapeutics, Inc. ("CTI") (Nasdaq and MTA: CTIC) announced that the U.S. Food and Drug Administration's ("FDA") Oncologic Drugs Advisory Committee ("ODAC") will review CTI's New Drug Application ("NDA") for pixantrone for the treatment of relapsed/refractory aggressive non-Hodgkin's lymphoma ("NHL") on March 22, 2010... (Source: Lymphoma / Leukemia News From Medical News Today)
PARP-1 Val762Ala polymorphism is associated with reduced risk of non-Hodgkin lymphoma in Korean males
Conclusion: The present data suggest that Val762Ala, Asp81Asp, and Lys352Lys polymorphisms and the haplotype-ACAAC in PARP-1 are associated with reduced risk of NHL in Korean males. (Source: BMC Medical Genetics - Latest articles)
Distinct virus found in cancer tissue of HIV-positive patients
University of Florida researchers studying samples from HIV-positive patients who died with a type of cancer called non-Hodgkins lymphoma have discovered the existence of two different HIV-1 populations — one that infects normal tissues and... (Source: OrlandoSentinel: Medical Research)
Children And Teens Less Likely Than Young Adults To Die Of Non-Hodgkin's Lymphoma
Young adults diagnosed with non-Hodgkin's lymphoma appear to have a higher risk of dying from the disease than do children and teens. Eric Tai, M.D., and colleagues at the Centers for Disease Control and Prevention, Atlanta, assessed survival information from cancer registries from 1992 to 2001 for 2,442 cases of non-Hodgkin's lymphoma (one of the most common cancers among young adults, affecting the white blood cells). This included 987 children and teens age 19 or younger and 1,455 young adults age 20 to 29... (Source: Health News from Medical News Today)
Children And Teens Less Likely Than Young Adults To Die Of Non-Hodgkin's Lymphoma
Young adults diagnosed with non-Hodgkin's lymphoma appear to have a higher risk of dying from the disease than do children and teens. Eric Tai, M.D... (Source: Lymphoma / Leukemia News From Medical News Today)
Differences in Non-Hodgkin Lymphoma Survival Between Young Adults and Children [Article]
Conclusions  Being a young adult at diagnosis and having a higher stage of disease at diagnosis were associated with higher risk of death from NHL. Increasing survival with NHL is dependent on receiving appropriate cancer therapy. Therefore, efforts to address survival should include improving enrollment in clinical trials as well as increasing access to care. (Source: Archives of Pediatrics)
Final analysis of the UKLG LY02 trial comparing 6–8 cycles of CHOP with 3 cycles of CHOP followed by a BEAM autograft in patients
In conclusion, no survival benefit was demonstrated for an early autograft in first response. (Source: British Journal of Haematology)
Dynamic contrast enhanced magnetic resonance imaging of diffuse spinal bone marrow infiltration in patients with hematological malignancies.
CONCLUSION: DCE-MRI of spine can be a useful tool in detecting diffuse marrow infiltration of hematological malignancies, while its parameters including E(max), ES, and TTP can reflect the malignancies' histological grade. PMID: 20191066 [PubMed - in process] (Source: Korean J Radiol)
New Cancer-Fighting Strategy That May Help Barrett's Esophagus Patients
A new study out of UCSF Helen Diller Family Comprehensive Cancer Center, one which has been studying the immune system, has identified a set of targets and bio-markers to battle solid tumors. Findings of this study center on discovery of signaling molecules that are major players in a biochemical mechanism linking certain actions of B cells to solid tumor growth. Lisa Coussens, PhD, lead author of the study, stated that the most notable implication of the study is that a drug in use for more than decade to treat non-Hodgkin's lymphoma, which is a cancer of the B cells, might be effective against other solid tumors. What does this mean for those individuals diagnosed with Barrett's esophagus? Biochemical and cellular studies during the past decade have shown that inflammation can promote ...
The Contributions of Improved Therapy and Earlier Detection to Cancer Survival Gains, 1988-2000
Prior literature has documented improvements in cancer survival over time. However, ambiguity remains over the relative contributions of improved treatment and earlier detection to survival gains. Using registry data, we developed a novel framework to estimate the relative contributions of advances in treatment and detection. Our approach compares changes in the probability of early detection, which we interpret as the effects of advances in detection, to improvements in stage-conditional survival, which we interpret as the effects of treatment. We applied this methodology using SEER data to estimate probabilities of early detection and stage-conditional survival curves for several cancers, by race, between 1988 and 2000. Survival increased for all of the cancers we examined, with blacks e...
Plasmablastic Lymphoma Involving the Parotid Gland
We report a case of an HIV positive man who developed a rapidly enlarging parotid mass. A core biopsy of the parotid mass was evaluated by routine microscopy, immunohistochemistry, and in situ hybridization. The tumor was comprised of sheets of large cells with abundant cytoplasm, eccentric nuclei and prominent nucleoli. The cells exhibited a plasmacytic immunophenotype including expression for CD38 and CD138. An in situ hybridization assay for Epstein-Barr virus was positive. These findings were diagnostic of plasmablastic lymphoma. Plasmablastic lymphoma is notoriously difficult to diagnose, particularly when it arises in unexpected sites outside of the oral cavity. As an aggressive lymphoma, plasmablastic lymphoma must be considered in the differential diagnosis of a high-grade ma...
Enhanced expression of lymphomagenesis-related genes in peripheral blood B cells of chronic hepatitis C patients.
In this study, we confirmed that peripheral blood B cells of chronic hepatitis C (CHC) patients were infected with HCV. Expression levels of activation-induced cytidine deaminase (AID) which are thought to be associated with occurrence of B-NHL were analyzed in these CHC B cells. It was demonstrated that AID mRNA/protein levels in CHC B cells were dramatically increased compared with those of healthy subjects. Furthermore, expression levels of several previously reported prognostic B-NHL marker genes in the B cell subset of CHC patients were increased. These results suggest a possible relationship between chronic HCV infection and B-lymphomagenesis. PMID: 20189883 [PubMed - as supplied by publisher] (Source: Clinical Immunology)
Primary non-Hodgkin lymphoma of cervix successfully treated with rituximab: Positron emission tomography images before and after therapy: A case report
Primary non-Hodgkin's lymphoma (NHL) of the genital tract is extremely rare (0.5%) and mostly originates from the ovary . The cervix lymphoma is 0.008% of the all cervix tumors and 2% of the all extranodal lymphomas in the females . The most common histological type is diffused large B cell lymphoma (DLBCL) . Primary cervical carcinoma, sarcoma or benign inflammatory conditions are kept in mind in differential diagnosis . Histopathological and immunohistochemical examinations of cervix biopsy specimen are required for definitive diagnosis . In staging, computerized tomography (CT) of the pelvis, abdomen and thorax or position emission tomography (PET–CT) can be used. There is not any established treatment protocol for primary cervix lymphoma (PCL) due to rarity of disease. Radiotherapy (...
Primary mantle cell lymphoma of the thyroid
Non-Hodgkin's lymphoma (NHL) incidence has rapidly increased since the 1970s. Incidence rates increased proportionally more for extranodal NHL than for nodal NHL . Primary NHL of the thyroid (PNHLT) is an uncommon diagnosis, accounting for 5% of all thyroid malignancies and 2% of primitive extranodal lymphomas, with an incidence of 0.5 per 100,000 population . (Source: Leukemia Research)
Identification of hypoxanthine as a urine marker for non-Hodgkin lymphoma by low-mass-ion profiling
Conclusions: The present study represents a good example of low-mass-ion profiling in the setting of disease screening using urine. This technique can be a powerful non-invasive diagnostic tool with high sensitivity and specificity for NHL screening. Furthermore, HX identified in the study may be a useful single urine marker for NHL screening. (Source: BMC Cancer)
Rituximab for the Treatment of Non-Hodgkins Lymphoma and Chronic Lymphocytic Leukaemia
(Source: Drugs)
Immune signatures in human PBMCs of idiotypic vaccine for HCV-related lymphoproliferative disorders
Hepatitis C virus (HCV) is one of the major risk factors for chronic hepatitis, which may progress to cirrhosis and hepatocellular carcinoma, as well as for type II mixed cryoglobulinemia (MC), which may further evolve into an overt B-cell non-Hodgkin's lymphoma (NHL).It has been previously shown that B-cell receptor (BCR) repertoire, expressed by clonal B-cells involved in type II MC as well as in HCV-associated NHL, is constrained to a limited number of variable heavy (VH)- and light (VL)-chain genes. Among these, the VK3-20 light chain idiotype has been selected as a possible target for passive as well as active immunization strategy.In the present study, we describe the results of a multiparametric analysis of the innate and early adaptive immune response after ex vivo stimulation of h...
Clinical impact and predisposing factors of delayed-onset neutropenia after autologous hematopoietic stem-cell transplantation for B-cell non-Hodgkin lymphoma: association with an incremental risk of infectious events.
CONCLUSIONS: Rituximab usage is an independent risk factor of DON. DON correlates with increased occurrence of infectious events. Careful follow-up would be needed after the onset of DON. PMID: 20172906 [PubMed - as supplied by publisher] (Source: Ann Oncol)
Bovine lactoferricin induces caspase-independent apoptosis in human B-lymphoma cells and extends the survival of immune-deficient mice bearing B-lymphoma xenografts.
Authors: Furlong SJ, Mader JS, Hoskin DW Although current treatments based on the use of B-cell-specific anti-CD20 monoclonal antibodies and aggressive combinatorial chemotherapy have improved the survival of patients suffering from B-cell non-Hodgkin's lymphoma (NHL), some individuals fail to respond to treatment and relapses remain common. New and more effective treatments for B-cell NHL are therefore required. Bovine lactoferricin (LfcinB) is a cationic antimicrobial peptide that is cytotoxic for several human tumor cell lines but does not harm healthy cells. Here we show that in vitro treatment with LfcinB caused Raji and Ramos human B-lymphoma cells to die by apoptosis, as indicated by DNA fragmentation, chromatin condensation, and nuclear disintegration. LfcinB killed B-lymphoma ...
A Proposed Method to Adjust for Selection Bias in Cohort Studies
Selection bias is a concern in cohort studies in which selection into the cohort is related to the studied outcome. An example is chronic infection with hepatitis C virus, where the initial infection may be asymptomatic for decades. This problem leads to selection of more severely ill individuals into registers of such infections. Cohort studies often adjust for this bias by introducing a time window between entry into the cohort and entry into the study. This paper describes and assesses a novel method to improve adjustment for this type of selection bias. The size of the time window is decided by calculating a standardized incidence ratio as a continuous function of the size of the time window. The resulting graph is used to decide on an appropriate window size. The method is evaluated b...
Depletion of peripheral blood B cells with Rituximab and phenotype characterization of the recovering population in a patient with follicular lymphoma
Abstract: The monoclonal antibody Rituximab is useful for treatment of patients with B-cell non-Hodgkin's lymphoma. We phenotypically analyzed reconstitution of peripheral B cells in a male patient with follicular lymphoma following their depletion with Rituximab. CD19+ and CD20+ B cell counts in peripheral blood decreased rapidly following Rituximab treatment. Six months after the end of treatment, a few CD19+ B cells were detected in peripheral blood. These cells had a naive B cell phenotype (IgD+, CD27−) and they expressed high levels of CD38 and CD24, which show that the B cell pool was repopulated mainly with immature, naive B cells. (Source: Leukemia Research)
Novel agents for B-cell non-Hodgkin lymphoma: Science and the promise
Summary: There has been tremendous insight gained in the last two decades from basic science research. New molecular targets in neoplastic cells are emerging and provide the rationale for clinical development of novel agents in non-Hodgkin lymphoma. These novel agents can be broadly categorized into two groups. The first is by immunotherapy which includes novel monoclonal antibodies and immunomodulating drugs, which takes advantage of or optimizes immune system function. The other group of drugs target small molecules that may play an important role in tumorigenesis. The mechanisms of anti-tumor activity include targeting apoptotic pathways, inhibition of proteasomes, mammalian target of rapamycin (mTOR), cyclin-dependent kinases and histone deacetylases. The purpose of this review is to f...
FDA Staff Raises Concerns About NHL Drug
WASHINGTON (MedPage Today) -- Reviewers from the Food and Drug Administration (FDA) questioned whether pixantrone (Pixuvri) effectively treats non-Hodgkin's lymphoma (NHL) patients who haven't responded to two prior chemotherapy treatments and said the drug has "substantial hematologic and cardiac toxicity." (Source: MedPage Today Public Health)
Characterization of genetic lesions in apoptosis-regulating and proliferation control genes in diffuse large B-cell non-Hodgkin's lymphoma
Conclusion&lt;/b&gt; : Our data suggest that simple p53 protein expression by IHC at the time of diagnosis may help to identify high-risk patients, who may benefit with more aggressive and newer treatments in addition to standard CHOP. (Source: Journal of Cancer Research and Therapeutics)
Primary non-Hodgkin lymphoma of the bone
Aziz FahadJournal of Cancer Research and Therapeutics 2009 5(4):331-331 (Source: Journal of Cancer Research and Therapeutics)
Atypical fibroxanthoma: a series of 25 cases
Conclusions Micrographic controlled surgery with wide 2 cm safety margins is the treatment of choice. A regular follow-up for the next 5 years is recommended. (Source: Journal of the European Academy of Dermatology and Venereology)
Monoclonal Antibodies in Advanced B-cell Lymphomas
he treatment of B-cell malignancies has been revolutionized by the availability of safe and effective monoclonal antibodies. The addition of rituximab to standard chemotherapy regimens prolongs the survival of patients with diffuse large B-cell lymphoma (DLBCL) and follicular non-Hodgkin lymphoma. Nevertheless, indolent and mantle cell lymphomas remain incurable, and 30% to 40% of patients with DLBCL still die from their disease. Much ongoing research has focused on optimizing monoclonal antibody use, integrating them into multiagent regimens, and developing newer antibodies. Attempts to improve on the efficacy of monoclonal antibody–based therapy have included altering the dosing schedule, optimizing patient selection, maintenance therapy, improving upon the rituximab molecule, radioimm...
Low levels of monoclonal small B-cells in the bone marrow of patients with diffuse large B-cell lymphoma of activated B-cell type but not of germinal center B-cell type.
Conclusions Bone marrow infiltration with DLBCL in patients with DLBCL, NOS is rare at diagnosis. By contrast, a high number of DLBCL, NOS of the ABC subtype but not of GCB subtype is associated with MSBC in the marrow. Whether these MSBC are precursors of DLBCL of the ABC type or arise in a common background that favours clonal B-cell expansion remains to be demonstrated. PMID: 20145271 [PubMed - as supplied by publisher] (Source: Haematologica)
Circulating Serum Free Light Chains As Predictive Markers of AIDS-Related Lymphoma [Aids-Related Cancer]
Conclusion Elevated FLCs may represent sensitive markers of polyclonal B-cell activation and dysfunction and could be useful for identifying HIV-infected persons at increased NHL risk. (Source: Journal of Clinical Oncology)
Pediatric Burkitt lymphoma presenting as acute pancreatitis: MRI characteristics
We present a 6-year-old boy who presented with pancreatitis and obstructive jaundice, which was the result of Burkitt lymphoma of the pancreas. The imaging findings of pancreatic involvement of Burkitt lymphoma on MRI are discussed and the contributory role of the radiologist in guiding the appropriate clinical work-up of this disease is highlighted. Content Type Journal ArticleCategory Case ReportDOI 10.1007/s00247-009-1475-3Authors John Amodio, SUNY Downstate Medical Center Department of Radiology 450 Clarkson Avenue Brooklyn NY 11203 USAJennie E. Brodsky, SUNY Downstate Medical Center Department of Radiology 450 Clarkson Avenue Brooklyn NY 11203 USA Journal Pediatric RadiologyOnline ISSN 1432-1998Print ISSN 0301-0449 (Source: Pediatric Radiology)
Abnormal fatty acid distribution of the serum phospholipids of patients with non-Hodgkin lymphoma
Abstract  The data about the fatty acid (FA) status of non-Hodgkin lymphoma (NHL) patients are poor. Therefore, the aim of this study was to investigate the FA profile of serum phospholipids in NHL patients related to the aggressiveness and clinical stage of NHL. We analyzed the FA profile of serum phospholipids in 47 newly diagnosed, untreated NHL patients and in 29 healthy subjects. Significantly higher (p < 0.001) levels of palmitic (16:0), oleic (18:1 n-9) and arachidonic acids (20:4 n-6), saturated and monounsaturated FA were found in NHL patients, while linoleic acid (18:2 n-6) and the levels of total polyunsaturated FA (PUFA), n-3 PUFA, eicosapentaenoic (20:5 n-3) and docosahexaenoic (DHA, 22:6 n-3) were significantly reduced (p < 0.01). The level of ole...
Correction: Antibody-Drug Conjugates for the Treatment of Non-Hodgkin's Lymphoma: Target and Linker-Drug Selection
(Source: Cancer Research)
Fine needle aspiration cytology and flow cytometry immunophenotyping of non-Hodgkin lymphoma: can we do better?
Conclusions: FNAC/FC is a fundamental tool in the diagnosis and classification of NHL but the exiguity of diagnostic material and other technical and clinical limitations will probably continue to limit further improvement of the technique. (Source: Cytopathology)
Immunomagnetic selection of CD34+ cells carried out in cryopreserved cell concentrates from a paediatric patient affected with non-Hodgkin lymphoma
(Source: Transfusion Medicine)
The Incidence of Cancer in a Population-Based Cohort of Canadian Heart Transplant Recipients
To assess the long-term risk of developing cancer among heart transplant recipients compared to the Canadian general population, we carried out a retrospective cohort study of 1703 patients who received a heart transplant between 1981 and 1998, identified from the Canadian Organ Replacement Register database. Vital status and cancer incidence were determined through record linkage to the Canadian Mortality Database and Canadian Cancer Registry. Cancer incidence rates among heart transplant patients were compared to those of the general population. The observed number of incident cancers was 160 with 58.9 expected in the general population (SIR = 2.7, 95% CI = 2.3, 3.2). The highest ratios were for non-Hodgkin's lymphoma (NHL) (SIR = 22.7, 95% CI = 17.3, 29.3), oral cancer (SIR = 4.3, 95% C...
Kikuchi-fujimoto disease.
Authors: Hutchinson CB, Wang E Abstract Kikuchi-Fujimoto disease, or histiocytic necrotizing lymphadenitis, is a self-limited condition, characterized by benign lymphadenopathy with associated fevers and systemic symptoms. It most commonly affects adults younger than 40 years of age and of Asian descent. Involved lymph nodes demonstrate paracortical areas of apoptotic necrosis with abundant karyorrhectic debris and a proliferation of histiocytes, plasmacytoid dendritic cells, and CD8(+) T cells in the absence of neutrophils. Kikuchi-Fujimoto disease is thought to have 3 evolving phases: proliferative, necrotizing, and xanthomatous. The etiology is unknown, although viruses and autoimmune mechanisms have been proposed. No specific laboratory tests contribute to the diagnosis. Diagnosis ...
Rituximab Lessened Effectiveness of Flu Vaccine
NEW ORLEANS — Non-Hodgkin's lymphoma patients treated with rituximab, especially rituximab-fludarabine regimens, have a significant deficit in humoral response to influenza vaccine. (Source: Rheumatology News)
Cross-Sectional Evaluation of Thoracic Lymphoma
In patients who have lymphoma, the presence and distribution of thoracic involvement is important in both tumor staging and treatment. Thoracic involvement in Hodgkin lymphoma (HL) is more common than in non-Hodgkin lymphoma (NHL). In HL, mediastinal lymphadenopathy with contiguous spread is a hallmark, and lung parenchymal involvement at the initial presentation is almost always associated with mediastinal lymphadenopathy. NHL is more heterogeneous and generally presents at a more advanced stage than HL. Most often, mediastinal involvement occurs as a disseminated or recurrent form of extrathoracic lymphoma. Bulky mediastinal disease with compression of adjacent structures can occur, particularly with high-grade subtypes of NHL and isolated lung disease without mediastinal lymphadenopathy...
Role of radiotherapy in the treatment of lymphomas of the gastrointestinal tract
In patients with gastrointestinal lymphoma the most frequently involved site is the stomach (60%–75% of cases), followed by the small bowel, ileum, cecum, colon and rectum. The most common histological subtypes are extranodal marginal zone B-cell lymphoma of the mucosa-associated lymphoid tissue (MALT) and diffuse large B-cell lymphoma (DLBCL). The role of radiotherapy is most definite in early stage gastric lymphoma.The therapeutic approach for patients with gastric Non Hodgkin lymphoma (NHL) has changed significantly over the last decades. The primary treatment of limited gastric MALT lymphoma consists of Helicobacter pylori eradication. In case of insufficient response to H. pylori eradication or in case H. pylori is absent, irradiation of the stomach and perigastric lymph nodes to a ...
GI-lymphomas in immunosuppressed patients (organ transplantation; HIV)
Gastrointestinal lymphoma plays a major role complicating different diseases presenting with immunosuppression, both primary and acquired immunodeficiency (incl. HIV, transplantation, immunosuppression following chemotherapy, or inflammatory bowel disease). Lymphoma in diseases with immunosuppression are clinically and pathologically heterogeneous, but share some features such as frequent involvement of extranodal sites, diffuse aggressive histology, B-cell lineage derivation, viral association with EBV and clinically aggressive courses. While gastrointestinal lymphoma in congenital immunodeficiency disorders seems to be a rare event inspite of higher prevalences, in post-transplant lymphoproliferative disorders (PTLD) the gastrointestinal tract is one of the most important organs of lymph...
Child cancer survivors have higher heart risk: Study
The cancer survivors had been diagnosed below the age of 21 with either leukemia, brain cancer, Hodgkin's lymphoma, non-Hodgkin's lymphoma, kidney cancer, neuroblastoma, soft tissue sarcoma, or bone cancer between 1970 and 1986.01/31/2010 (Source: Kidney Cancer Association)
Non-Hodgkin lymphoma (NHL) subtypes defined by common translocations: Utility of fluorescence in situ hybridization (FISH) in a case–control study
Abstract: We used fluorescence in situ hybridization (FISH) assays to identify t(14;18) translocations in archival paraffin-embedded tumor sections from non-Hodgkin lymphoma (NHL) cases enrolled in a population-based study. t(14;18) was identified in 54% of 152 cases, including 39% of diffuse large cell lymphomas (26 of 66 cases) and 84% of follicular lymphomas (36 of 43 cases). Eighty-seven percent of t(14;18)-positive cases and 57% of t(14;18)-negative cases expressed bcl-2. FISH assays detected twice as many t(14;18)-positive follicular lymphomas as PCR assays. Overall, study findings support the use of FISH assays to detect t(14;18) in archival tumor samples for epidemiologic studies of NHL subtypes. (Source: Leukemia Research)
Radioimmunotherapy of Lymphoma: Bexxar and Zevalin
This article reviews the basis for dose selection, the nuclear medicine procedures involved, the results obtained to date, and issues related to patient and staff safety. (Source: Seminars in Nuclear Medicine)
Dose Intensified Molecular Targeted Radiotherapy for Cancer—Lymphoma as a Paradigm
Although most patients with locoregional cancer are cured by surgery, radiotherapy, chemotherapy, and combinations thereof, those with distant metastases are not despite systemic chemotherapy. These patients respond to local radiotherapy but generally need systemic therapy. Non-Hodgkin's lymphoma (NHL) provides a paradigm for the role of molecular targeted radiotherapy (MTRT) because these patients have multifocal disease in most cases. Although patients with NHL achieve remissions after multiple cycles of chemotherapy, less than one half of those with aggressive NHL are cured and almost none of those with low grade NHL. Furthermore, NHL, like other cancers, becomes chemoresistant, yet remains responsive to radiotherapy. MTRT, radiation targeted by molecules, is a good strategy for the tre...
T-Cell Lymphoblastic Lymphoma of the Sternum [DIAGNOSIS IN ONCOLOGY]
(Source: Journal of Clinical Oncology)
Immune Modulation by Non-Hodgkin Lymphoma in a Patient with Two Primary Intestinal T-Cell Lymphomas and Long-Standing Celiac Disease
Digestion 2010;81:231–234 (DOI:10.1159/000269810) (Source: Digestion)
Non-Hodgkin's lymphoma presenting as an isolated soft-tissue chest wall mass [Images in cardio-thoracic surgery]
(Source: European Journal of Cardio-Thoracic Surgery)
CNOP (mitoxantrone) chemotherapy is inferior to CHOP (doxorubicin) in the treatment of patients with aggressive non-Hodgkin lymphoma (meta-analysis)
Source: DARE Area: Evidence > Drug Class Focused Reviews CRD Summary: This review concluded that doxorubicin (CHOP) chemotherapy was more effective than mitoxantrone (CNOP) at equitoxic (myelosuppression) doses with regard to complete remission in patients with aggressive non-Hodgkin lymphoma. CHOP was associated with greater risk of adverse effects. Given several limitations, including the small number of included studies and the potential for reporting bias, the authors' conclusions may not be reliable.  CRD Commentary: The review question and supporting inclusion criteria were clear. The literature search was adequate, using two electronic databases and other appropriate sources, including a search for unpublished data, thus limiting the possibility that potentially relevant pa...
Late potentials and QT dispersion after high-dose chemotherapy in patients with non-Hodgkin lymphoma
The most common cardiotoxic effects of high-dose cyclophosphamide (CY) are electrocardiographic changes and transient arrhythmias. Therefore, we prospectively assessed serial electrocardiogram (ECG) and signal-averaged electrocardiogram (SAECG) recordings in 30 adult patients with non-Hodgkin lymphoma (NHL) receiving high-dose CY as part of high-dose chemotherapy (HDT) regimen. All patients were treated with anthracyclines earlier. Heart-rate-corrected QT interval and QT dispersion (QTc and QTc dispersion) were measured from ECG. QRS duration and late potentials (LPs) were analysed from SAECG. Both ECG and SAECG were recorded 1 day (d) prior to HDT (d[minus]7) at baseline, and 1 day (d[minus]2), 7 days (d+7), 12 days (+12) and 3 months (m+3) after HDT. Stem cells were infused on day 0 (d0)...
Divided Vermont Supreme Court Affirms Denial Of Benefits For Estate Of Firefighter
MONTPELIER, Vt. - A divided Vermont Supreme Court on Jan. 15 affirmed summary judgment for a workers' compensation provider and the exclusion of causation expert opinion for a claimant who failed to establish a causal connection between his work as a firefighter and the non-Hodgkin's lymphoma of which he died (Estate of Albert George v. Vermont League of Cities and Towns, No. 08-374, Vt. Sup.; 2010 Vt. LEXIS 2). Full story on lexis.com (Source: LexisNexis® Mealey's™ Emerging Toxic Torts Legal News)
Phase 2 study of intrathecal, long-acting liposomal cytarabine in the prophylaxis of lymphomatous meningitis in human immunodeficiency virus-related non-Hodgkin lymphoma
Patients with aggressive non-Hodgkin lymphoma (NHL) develop central nervous system (CNS) progression or recurrence during the course of their disease. Patients with human immunodeficiency virus (HIV)-NHL often develop CNS progression despite the use of prophylaxis. Liposomal cytarabine (DepoCyte) has shown activity in lymphomatous meningitis, but there are limited data for prophylaxis.Between May 2006 and December 2008, a phase 2 study of intrathecal liposomal cytarabine was performed at the dose of 50 mg in 30 patients with HIV-NHL, with the aim of evaluating feasibility and activity for prophylaxis.Liposomal cytarabine was well tolerated, with headache grade I to III being the most frequent side effect in 40% of patients. With a median follow-up of 10.5 months, only 1 (3%) patient develo...
Leukemia, non-Hodgkin's lymphoma, and Wilms tumor in childhood: the role of birth weight
Abstract  There is emerging evidence that higher birth weight is associated with increased risk of cancer, in particular childhood leukemia. The purpose of this paper is to study whether this correlation is also significant with other childhood cancer. For this, we conducted a case–control study including 410 childhood cancer patients and 1,575 matched controls to investigate birth weight as a risk factor for leukemia, Wilms tumor, and non-Hodgkin's lymphoma. The estimated risk for all cancers has been found to be statistically and significantly higher in birth weight of more than 4,000 g (odds ratio, 2.50 and 95% confidence intervals (CI), 1.72–3.63). For leukemia, the estimated risk was 1.86 (95% CI, 1.04–3.30), for non-Hodgkin lymphoma, 1.99 (95% CI, 1.08–3....
Clinical characteristics and outcome analysis of pediatric B-cell non-Hodgkin's lymphoma. Experience with FAB-LMB 96 and UKCCSG B-cell NHL guidelines in a developing country
Conclusion: Late presentation with advanced disease, poor nutritional status and high risk of exposure to infective agents all contribute to the high mortality in patients treated with intensive protocols in resource-poor countries. (Source: Asia-Pacific Journal of Clinical Oncology)
AA-type amyloidosis in association with non-Hodgkin's lymphoma following CMV viremia: Autopsy case
Amyloidosis in non-Hodgkin's lymphoma (NHL) is known to be of the AL type, and AA-type amyloidosis in NHL is extremely rare. Herein is reported an autopsy case of follicular lymphoma that transformed to diffuse large B-cell lymphoma (DLBCL) in a relapse associated with systemic AA amyloidosis. CMV infection in an immunocompromised state with chemotherapy against DLBCL may have been involved in amyloid accumulation. The serum amyloid A (SAA)1 gene polymorphism, SAA1.2/1.3, might have also been another factor in this case, considering the risk of AA amyloidosis in Japanese patients with rheumatoid arthritis. (Source: Pathology International)
Bowel Obstruction after Treatment of Intra-Abdominal Tumors
Purpose: Tumors of the solid viscera are one of the most common types of pediatric malignancies. Due to the intra-abdominal location of many of these neoplasms, laparotomy and/or bowel resection are often necessary. Additionally, chemotherapy and radiation therapy may lead to bowel injury and obstruction. We reviewed our data over an eleven-year period to identify the incidence of obstruction as well as factors associated with its development. Methods: A retrospective data analysis of all patients diagnosed with intra-abdominal Wilms' tumor, rhabdomyosarcoma, neuroblastoma, Hodgkin's and non-Hodgkin's lymphoma at a single institution from 1997 to 2007 was conducted. Data collected included demographic factors, operations, incidence of small bowel obstruction (SBO) and the use of adjuvant o...
Intramuscular manifestation of non-Hodgkin lymphoma and myeloma: prevalence, clinical signs, and computed tomography features.
CONCLUSION: NHL mostly manifests as diffuse muscle enlargement, whereas myelomas form focal intramuscular masses. Nevertheless, CT and MR appearances are nonspecific and can be misinterpreted as muscle sarcoma or inflammatory disease. Although rare, muscle involvement should be considered in the differential diagnosis of muscle disorders in patients with non-Hodgkin lymphoma and myeloma. PMID: 20088640 [PubMed - in process] (Source: Acta Radiologica)
The impact of cancer and quality of life for post-treatment non-Hodgkin lymphoma survivors
This study examines the association between the Impact of Cancer Version 2 Scales (IOCv2) and these outcomes in a large sample of survivors of adult non-Hodgkin lymphoma (NHL).Methods: Participants completed a mailed survey to assess physical and mental health (SF-36), cancer-specific QOL (FACT-G) and perceived impact of cancer (IOCv2). Hierarchical multiple regression models, in which demographic, clinical, psychosocial and IOCv2 measures were added sequentially, were employed to evaluate their contribution to explain variance in SF-36 and FACT-G scores.Results: A total of 652 post-treatment NHL survivors participated. Survivors with comorbidities and negative appraisals of life threat and treatment intensity reported worse physical and mental health and QOL (all p (Source: Psycho-Oncolog...
Bendamustine plus rituximab offers new standard of care for treatment of NHL and indolent lymphoma
There was good news at ASH 2009 on promising treatments for indolent lymphoma and aggressive non-Hodgkin's lymphoma. (Source: Cancer Network)
Immunohistochemical localization of cellular NFATc1 does not predict clinical responses to ciclosporin in subcutaneous panniculitis-like T-cell non-Hodgkin lymphoma
(Source: British Journal of Dermatology)
Immunohistochemical localization of cellular NFATc1 does not predict clinical responses to ciclosporin in subcutaneous panniculitis-like T-cell non-Hodgkin lymphoma.
Authors: Tauro S, Maccallum S, Groves MJ, Rojnuckarin P, Assanasen T, Feldman AL, Robson A, Marschalkó M, Kini H, Alzolibani AA, Al Robaee A, Al Shobaili HA, Alfawzan S, Goodlad JR, Kernohan N, Hummel M, Sterry W, Assaf C PMID: 20096007 [PubMed - as supplied by publisher] (Source: The British Journal of Dermatology)
Tumor Necrosis Factor (TNF) and Lymphotoxin-{alpha} (LTA) Polymorphisms and Risk of Non-Hodgkin Lymphoma in the InterLymph Consortium
In an International Lymphoma Epidemiology Consortium pooled analysis, polymorphisms in 2 immune-system-related genes, tumor necrosis factor (TNF) and interleukin-10 (IL10), were associated with non-Hodgkin lymphoma (NHL) risk. Here, 8,847 participants were added to previous data (patients diagnosed from 1989 to 2005 in 14 case-control studies; 7,999 cases, 8,452 controls) for testing of polymorphisms in the TNF –308G>A (rs1800629), lymphotoxin- (LTA) 252A>G (rs909253), IL10 –3575T>A (rs1800890, rs1800896), and nucleotide-binding oligomerization domain containing 2 (NOD2) 3020insC (rs2066847) genes. Odds ratios were estimated for non-Hispanic whites and several ethnic subgroups using 2-sided tests. Consistent with previous findings, odds ratios were increased for "new" ...
Genetic variation in chromosomal translocation breakpoint and immune function genes and risk of non-Hodgkin lymphoma
Conclusions  We found no support for a role of the studied variants in BCL2, CCND1, or MYC in risk of NHL or subtypes, but we provide further evidence of putative susceptibility loci in TNF and IL10 for specific NHL subtypes. Content Type Journal ArticleCategory Original paperDOI 10.1007/s10552-010-9504-yAuthors Pia Fernberg, Karolinska Institutet Department of Medical Epidemiology and Biostatistics P.O. Box 281 171 77 Stockholm SwedenEllen T. Chang, Northern California Cancer Center Fremont CA USAKristina Duvefelt, Karolinska Institutet Department of Biosciences at Novum, Clinical Research Centre Stockholm SwedenHenrik Hjalgrim, Statens Serum Institut Department of Epidemiology Research Copenhagen DenmarkSandra Eloranta, Karolinska Institutet Department of Medical Epide...
Cochrane review: Interventions for previously untreated patients with AIDS-associated Non-Hodgkin´s Lymphoma
Source: Cochrane Library Area: Evidence > Disease Focused Reviews Background Human immunodeficiency virus (HIV) infection is known to be associated with an increased risk of non-Hodgkin's lymphoma (NHL). The majority of lymphomas (>80%) occurring during immunosuppression are aggressive B-cell in origin and have a high-to-intermediate histology grade. Treatment of NHL is not standardized.   Objectives To assess the clinical effectiveness and safety of single agent or combination chemotherapy with or without immunochemotherapy (rituximab) and with or without highly active antiretroviral therapy (HAART) on overall survival (OS) and disease-free survival (DFS) for previously untreated patients with AIDS-related NHL.   Search strategy The Cochrane Central Register of Cont...
FDG PET/CT of Extranodal Involvement in Non-Hodgkin Lymphoma and Hodgkin Disease [RSNA Education Exhibits]
The role of FDG PET/CT in the evaluation of extranodal Hodgkin disease and non-Hodgkin lymphoma is discussed and illustrated with emphasis on the typical findings of common and uncommon extranodal sites of involvement and potential imaging pitfalls. (Source: Radiographics recent issues)
Merkel cell carcinoma metastatic to the thyroid gland: Aspiration findings and differential diagnosis
Clinically diagnosed metastasis to the thyroid gland is exceptionally rare and may present diagnostic issues on fine needle aspiration. The most common primary sites of metastases to the thyroid are cancers of the lung, breast, skin (especially melanoma), colon, and kidney. Herein, we report a case of metastatic Merkel cell carcinoma to the thyroid presenting as a 2.1-cm solid nodule in a 50-year-old male with a previous history of Merkel cell carcinoma of the upper extremity. The aspirates were moderately to highly cellular featuring small to intermediate sized cells with scant to no cytoplasm, round-to-oval nuclei with finely dispersed chromatin, and predominantly arranged as scattered single cells. There was focal nuclear molding, numerous mitoses, and karyorrhectic nuclei. The differen...
Diffuse Large B-Cell Lymphoma in an Hepatitis C Virus-Infected Patient Presenting With Lactic Acidosis and Hypoglycemia.
Authors: Keller BC, Nussensveig D, Dowell JE Non-Hodgkin lymphoma can produce a number of metabolic derangements including, in rare instances, lactic acidosis. This case illustrates an example of significant lactic acidosis and hypoglycemia secondary to diffuse large B-cell lymphoma with hepatic involvement in a patient with hepatitis C infection. A review of the literature on the occurrence of lactic acidosis and lymphoma, including the risk factors for its development and the resultant prognosis, are discussed. In addition, the evidence linking hepatitis C infection and lymphoma are reviewed. PMID: 20087167 [PubMed - as supplied by publisher] (Source: The American Journal of the Medical Sciences)
Time to Treatment Response in Patients with Follicular Lymphoma Treated with Bortezomib Is Longer Compared with Other Histologic Subtypes.
CONCLUSIONS: These data suggest that bortezomib has significant single agent activity in patients with FL, and that longer durations of treatment may improve overall response. Clin Cancer Res; 16(2); 719-26. PMID: 20068103 [PubMed - as supplied by publisher] (Source: Cell Research)
Romidepsin and Belinostat Synergize the Antineoplastic Effect of Bortezomib in Mantle Cell Lymphoma.
CONCLUSIONS: Collectively, these data strongly suggest that HDACI such as romidepsin or belinostat in combination with a proteasome inhibitor could represent a novel and rationale platform for the treatment of MCL. Clin Cancer Res; 16(2); 554-65. PMID: 20068080 [PubMed - as supplied by publisher] (Source: Cell Research)
Gene Mutations Reveal Potential New Targets for Treating a Type of Non-Hodgkin's Lymphoma
Researchers have discovered genetic mutations that may contribute to the development of an aggressive form of non-Hodgkin's lymphoma. These findings provide insight into a mechanism that cancer cells may use to survive, thus identifying potential new targets for treatment of the disease. The study conducted by researchers at the National Cancer Institute (NCI), the National Institute for Allergy and Infectious Diseases, and the National Human Genome Research Institute, components of the National Institutes of Health, and colleagues appeared Jan. 7, 2010, in Nature. (Source: National Institutes of Health (NIH) News Releases)
Second-line age-adjusted International Prognostic Index in patients with advanced non-Hodgkin lymphoma after T-cell depleted allogeneic hematopoietic SCT
Authors: M-A Perales, R Jenq, J D Goldberg, A S Wilton, S S E Lee, H R Castro-Malaspina, K Hsu, E B Papadopoulos, M R M van den Brink, F Boulad, N A Kernan, T N Small, S Wolden, N H Collins, M Chiu, G Heller, R J O'Reilly, T Kewalramani, J W Young & A A Jakubowski (Source: Bone Marrow Transplantation)
VEGF-A promotes lymphoma tumour growth by activation of STAT proteins and inhibition of p27KIP1 via paracrine mechanisms
Abstract: Increased levels of circulating VEGF-A have been demonstrated in patients with non-Hodgkin lymphoma (NHL) and are associated with progressive disease and poor clinical outcome. We investigated the role of VEGF-A in lymphoma tumour growth on a molecular level in order to identify the mechanism of VEGF-A-promoted tumour growth and to identify the potential targets for therapy. We used a model in which Daudi (human Burkitt lymphoma) tumour cells were transduced with VEGF-A165 or an empty vector (negative control) and subcutaneously injected in NOD/SCID mice. The weight of tumours overexpressing VEGF-A was increased 4-fold compared to that of control tumours (p (Source: European Journal of Cancer)
Autoimmune haemolytic anaemia associated with mantle cell lymphoma.
We describe herein a case of MCL diagnosed in an initially asymptomatic 66-year-old woman who developed transfusion-dependent AIHA 6 months later coincident with lymphoma progression. The AIHA failed to respond satisfactorily to conventional treatment (high-dose oral prednisolone) but rapidly resolved following commencement of non-rituximab-containing combination chemotherapy in parallel with complete remission of the lymphoma. This is the first of such cases to be described in the literature and confirms that the immune environment of MCL can predispose to AIHA in the same way as in other lymphoma subtypes. Despite this being an infrequent occurrence, clinicians should be aware that AIHA is a potential complication of MCL and may be more successfully controlled by treating the underlying ...
Gene Mutations Reveal Potential New Targets For Treating A Type Of Non-Hodgkin's Lymphoma
Researchers have discovered genetic mutations that may contribute to the development of an aggressive form of non-Hodgkin's lymphoma. These findings provide insight into a mechanism that cancer cells may use to survive, thus identifying potential new targets for treatment of the disease... (Source: Lymphoma / Leukemia News From Medical News Today)
Gene Mutations Reveal Potential New Targets For Treating A Type Of Non-Hodgkin's Lymphoma
Researchers have discovered genetic mutations that may contribute to the development of an aggressive form of non-Hodgkin's lymphoma. These findings provide insight into a mechanism that cancer cells may use to survive, thus identifying potential new targets for treatment of the disease. The study conducted by researchers at the National Cancer Institute (NCI), the National Institute for Allergy and Infectious Diseases, and the National Human Genome Research Institute, components of the National Institutes of Health, and colleagues appeared Jan. 7, 2010, in Nature... (Source: Health News from Medical News Today)
An Evaluation of the Cost-Effectiveness of Rituximab in Combination with Chemotherapy for the First-Line Treatment of Follicular Non-Hodgkin's Lymphoma in the UK
Conclusions: The addition of rituximab to chemotherapy in advanced FL was found to be highly cost-effective in the UK. (Source: Value in Health)
Phase I Study of Intravenous Vascular Endothelial Growth Factor Trap, Aflibercept, in Patients With Advanced Solid Tumors [Phase I and Clinical Pharmacology]
Conclusion IV VEGF Trap was well tolerated at the dose levels tested. Pharmacodynamic and pharmacokinetic markers were indicative of VEGF blockade. (Source: Journal of Clinical Oncology)
Immunoglobulin G Fc Receptor Fc{gamma}RIIIa 158 V/F Polymorphism Correlates With Rituximab-Induced Neutropenia After Autologous Transplantation in Patients With Non-Hodgkin's Lymphoma [Hematologic Malignancies]
Conclusion The high affinity FcRIIIa 158 V allele is associated with rituximab-induced neutropenia after autologous transplantation. This is a potential tool to identify a high-risk population for developing neutropenia after antibody therapy. (Source: Journal of Clinical Oncology)
Quality of life, characteristics and survival of patients with HIV and lymphoma
Conclusion  HIV-infected NHL patients had worse QOL and survival than uninfected patients, due to a combination of co-morbidity, aggressive histology and lack of social support. However, their emotional well-being was comparable to that of uninfected NHL patients and better than historical norms for the HIV-infected. Content Type Journal ArticleDOI 10.1007/s11136-009-9565-0Authors Catherine Diamond, University of California Irvine Department of Epidemiology Irvine CA 92697-7555 USAThomas H. Taylor, University of California Irvine Department of Epidemiology Irvine CA 92697-7555 USAHoda Anton-Culver, University of California Irvine Department of Epidemiology Irvine CA 92697-7555 USA Journal Quality of Life ResearchOnline ISSN 1573-2649Print ISSN 0962-9343 (Source:...
Gene Mutations Reveal Potential New Targets for Treating a Type of Non-Hodgkin's Lymphoma
: Researchers discover genetic mutations that may contribute to the development of an aggressive form of non-Hodgkin's lymphoma. These findings provide insight into a mechanism that cancer cells may use to survive, thus identifying potential new targets for treatment of the disease. The study conducted by researchers at the National Cancer Institute (NCI), the National Institute for Allergy and Infectious Diseases, and the National Human Genome Research Institute, components of the National Institutes of Health, and colleagues appeared Jan. 7, 2010, in Nature. (Source: NHGRI-Related News)
IL-7 receptor is expressed on adult pre-B-cell acute lymphoblastic leukemia and other B-cell derived neoplasms and correlates with expression of proliferation and survival markers.
Authors: Sasson SC, Smith S, Seddiki N, Zaunders JJ, Bryant A, Koelsch KK, Weatherall C, Munier ML, McGinley C, Yeung J, Mulligan SP, Moore J, Cooper DA, Milliken S, Kelleher AD The interleukin (IL)-7 receptor (IL-7R) is expressed on human pre-B but not mature B-cells. We hypothesised that aberrant expression of IL-7R contributes to B-cell oncogenesis. Surface expression of IL-7R components CD127 and CD132, and intracellular Ki-67 and Bcl-2 were examined by flow cytometry on peripheral blood or bone marrow mononuclear cells (PBMC; BMMC) from patients with B-cell derived neoplasms, chronic human immunodeficiency virus type-1 (HIV-1) infection alone, or healthy volunteers. Plasma IL-7, IL-2, IL-4, IL-6, IL-10, IL-21, TNF-alpha, IFN-gamma and BAFF were measured by enzyme-linked immuno-sor...
Genetic Clues May Point to Better Lymphoma Treatments
Findings could help those with a type of non-Hodgkin's lymphoma, researchers say Source: HealthDay Related MedlinePlus Topics: Genes and Gene Therapy, Lymphoma (Source: MedlinePlus Health News)
Cancer incidence in people with AIDS in Italy
In conclusion, standardized IRs for non-AIDS-defining cancers have not risen in the HAART period, even if crude IRs of these cancers increased. This scenario calls, however, for the intensification of cancer-prevention strategies, notably smoking cessation and screening programs, in middle-aged HIV-patients. (Source: International Journal of Cancer)
The Function Of The Protein CD20
Antibodies directed against the protein CD20, which is expressed by immune cells known as B cells, are used to treat B cell non-Hodgkin lymphoma and rheumatoid arthritis. Despite this, the function of CD20 has not been determined. Now, a team of researchers led by René van Lier, at the Academic Medical Center, The Netherlands, has determined that CD20 has a nonredundant role in generating optimal B cell immune responses by analyzing a patient lacking the protein... (Source: Health News from Medical News Today)
The Function Of The Protein CD20
Antibodies directed against the protein CD20, which is expressed by immune cells known as B cells, are used to treat B cell non-Hodgkin lymphoma and rheumatoid arthritis. Despite this, the function of CD20 has not been determined... (Source: Immune System / Vaccines News From Medical News Today)
Susceptibility of mantle cell lymphomas to reovirus oncolysis
Abstract: Mantle cell lymphoma (MCL) an incurable B-cell, non-Hodgkin lymphoma (NHL) urgently requires new treatments. We assessed reovirus mediated oncolysis in a panel of human MCL cell lines. In vitro, we found the cytopathic effect of reovirus infection ranged from high to very limited and correlated with levels of Ras activation. In vivo, a single reovirus injection intra-tumorally resulted in complete regression of both the injected and the contra-lateral tumor in a subcutaneous bi-tumor model, in one out of three cell lines tested. Reovirus treatment of MCL seems feasible but will need to be guided by the presence of molecular determinants of reovirus susceptibility. (Source: Leukemia Research)
Bone marrow necrosis and fat embolism syndrome presented as conus medullaris syndrome in a patient with primary mediastinal large B-cell lymphoma
Bone marrow necrosis (BMN) is defined as necrosis of the medullary stroma and myeloid tissues in large areas of the hematopoietic bone marrow (BM) leaving an amorphous eosinophilic background, poorly defined necrotic cells and preserved cortical bone . It is associated with a poor prognosis . Hematologic malignancies, such as acute and chronic leukemia, Hodgkin's and non-Hodgkin's lymphoma, chronic myeloproliferative disorders, and some solid tumors are most commonly associated with BMN . A rare but life-threatening complication of BMN is the fat embolism syndrome (FES) . Fat globules or necrotic BM, after being embolized to the pulmonary arteries, can pass pulmonary capillaries, patent foramen ovale or arteriovenous shunts and enter the left circulation damaging organs. Fat embolism (FE) ...
Primary hepatic MALT lymphoma associated with primary biliary cirrhosis
Primary hepatic lymphoma is a rare disease. Primary low-grade lymphoma of the liver is uncommon and accounts for less than 1% of all cases of extranodal lymphoma . Most cases of hepatic lymphoma represent the secondary involvement of intermediate or high-grade non-Hodgkin's lymphoma . Similar to extranodal lymphomas from other anatomic regions, most primary hepatic lymphomas are diffuse large B cell lymphomas . Primary hepatic marginal zone lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma) was first introduced in 1995. These lymphomas are often associated with a history of chronic inflammation or autoimmune disease . In this case report, we describe a woman with primary hepatic MALT lymphoma associated with primary biliary cirrhosis (PBC). (Source: Leukemia Research)
Diabetes insipidus as main presentation of non-Hodgkin's lymphoma with hypophyseal involvement: Two case reports
Non-Hodgkin's lymphoma (NHL) presenting with diabetes insipidus (DI) in consequence of hypophyseal lesion is relatively rare. The condition may occur as either primary central nervous system (CNS) lymphoma or systemic lymphoma with meningeal or parenchymal involvement . As the latter, it is more often in intermediate and high grade malignant NHL . Although a few unusual localizations in CNS have been reported, the data about pituitary involvement with DI as first complaint of NHL is very limited. Here, we report on two cases who complained of DI before NHL was diagnosed. Brain MRI showed absence of the normal hyperintense signal at the posterior lobe of the pituitary in both cases, slight enlargement of the pituitary stalk in one patient with Burkitt lymphoma, and an empty sella with defor...
Fcgamma receptor IIIA polymorphisms and efficacy of rituximab therapy on Chinese diffuse large B-cell lymphoma.
CONCLUSIONS: The distribution of FcgammaRIIIA polymorphisms in this B-cell lymphoma population shows that VF is most frequently expressed, followed by VV and FF. Patients with the FcgammaRIIIA VV and VF types are more sensitive to the initial treatment of rituximab combined with chemotherapy and have superior long-term survival compared with those with FF. Nevertheless, FcgammaRIIIA polymorphisms do not predict prognosis independently. PMID: 20137370 [PubMed - in process] (Source: Chinese Medical Journal)
Primary effusion lymphoma: an untrivial differential diagnosis for ascites.
Authors: Ceran F, Aydin Y, Ozçakar L, Han U, Yildiz M A primary effusion lymphoma is a rare type of non-Hodgkin's lymphoma where serous cavities are involved. That-cause peritoneal, pleural and pericardial effusions without any lymphadenopathy. They affect immunosuppressive patients with human herpes virus-8 being the suspected etiological agent. The prognosis is usually poor despite treatment. Herein, the case of an immunocompetent patient with ascites and pleural effusion diagnosed as primary effusion lymphoma is presented and discuss the case in the light of the current literature. PMID: 20046433 [PubMed - in process] (Source: Yonsei Medical Journal)
Targeted therapy in haematological malignancies
The recent and rapid development of molecularly targeted therapy is best illustrated by advances in the management of haematological malignancy. In myeloid diseases we have seen dramatic improvements in the overall survival and quality of life for patients with chronic myeloid leukaemia treated with ABL and Src/ABL kinase inhibitors and we are poised to discover whether JAK2 inhibitors may offer similar benefit in myeloproliferative diseases. For acute myeloid leukaemia, the introduction of ATRA and myelotarg have had major impacts on the design of therapy regimens and many novel targeted agents, including farnesyl transferase, FLT3 and histone deacetylase inhibitors, are now in clinical trial. In lymphoid malignancies the highlight has been the introduction of rituximab, with significant ...
Amelioration of Oxaliplatin Neurotoxicity by Drugs in Humans and Experimental Animals: A MiniReview of Recent Literature
Abstract: The broad spectrum anti-neoplastic drug oxaliplatin is a third-generation platinum compound that inhibits DNA synthesis, mainly by causing intrastrandal cross-links in DNA. The drug is particularly useful alone and in combination with flurouracil and leucovorin in colorectal cancer, but it is also used for other cancers such as those of the ovary, lung, breast and liver, as well as non-Hodgkin's lymphoma. The drug is known to cause neurological, gastrointestinal and haematological toxicities. Neurotoxicity occurs in most of the treated patients and is considered to be a serious limitation for the use of the drug. The mechanism of the neurotoxicity is not known with certainty but may involve prolongation of sodium channels opening. Strategies to ameliorate oxaliplatin neurotoxicit...
The role of macrophages in the development and progression of AIDS-related non-Hodgkin lymphoma.
Authors: Huysentruyt LC, McGrath MS Despite HAART, patients infected with HIV develop NHL at a significantly higher level than the noninfected population. The primary difference between lymphoma in non-HIV-infected individuals and those with ARL is that ARL is consistently high-grade and metastatic. The emergence of ARL is associated with the presence of macrophage viral reservoirs, similar to what has been observed for HAD. HIV-infected macrophages, as seen by histology and HIV p24 staining, are present in approximately half of ARLs. Macrophage reservoirs recruit additional immune cells, including monocytes/macrophages, through the release of chemoattractants. Additionally, TAM are known to promote tumor progression for most cancer types, including lymphomas. This review will highligh...
Alcohol consumption and non-Hodgkin lymphoma survival
Conclusions  Our results suggest a moderate relationship between pre-diagnostic alcohol consumption and NHL survival, particularly for DLBCL. The results need to be replicated in larger studies. Implications for cancer survivors  Pre-diagnostic behaviors might impact the prognosis and survival of NHL patients. Content Type Journal ArticleDOI 10.1007/s11764-009-0111-4Authors Xuesong Han, Yale University School of Public Health New Haven CT 06520 USATongzhang Zheng, Yale University School of Public Health New Haven CT 06520 USAFrancine M. Foss, Yale University School of Medicine New Haven CT 06520 USAShuangge Ma, Yale University School of Public Health New Haven CT 06520 USATheodore R. Holford, Yale University School of Public Health New Haven CT 06520 US...
Correlation of pretransplant and early post-transplant response assessment with outcomes after reduced-intensity allogeneic hematopoietic stem cell transplantation for non-Hodgkin's lymphoma
Chemotherapy sensitivity, defined simply as at least a partial response to chemotherapy, is an important outcome predictor for non-Hodgkin lymphoma (NHL) patients undergoing reduced-intensity allogeneic hematopoietic stem cell transplantation (allo-HCT). The authors hypothesized that further differentiation of chemotherapy sensitivity by specific response, complete remission (CR) versus partial remission (PR) versus stable disease (SD) versus progression of disease (PD), correlates with post-transplant outcomes.The impact of pretransplant and early (28 days) post-transplant disease response on transplant outcomes was analyzed in 63 NHL patients treated with reduced-intensity allo-HCT.The 3-year event-free survival (EFS) and overall survival (OS) (median potential follow-up after reduced-in...
Histopathologic classification of 171 cases of canine and feline non-Hodgkin lymphoma according to the WHO
A retrospective collection of 171 lymphoid neoplasms (123 dogs and 48 cats) was classified according to the Revised European[ndash]American Lymphoma (REAL) classification, adopted in 2002 by the World Health Organization (WHO), to evaluate the WHO system for categorization of canine and feline neoplasms. Microscopic examination was performed after standard hematoxylin[ndash]eosin staining and immunohistochemical labelling for B (CD79a) or T (CD3) cell phenotypes. B-cell lymphomas were prevalent in dogs and T-cell lymphomas in cats. B-Large cell lymphoma (B-LCL) frequently showed plasmacytoid differentiation; notably, two canine plasma cell tumours (PCT) expressed both CD79 and CD3. There were difficulties in differentiating B-lymphoblastic lymphoma (B-LBL) from Burkitt-type lymphoma. Furth...
Assessment of Metabolic Response to Radioimmunotherapy with 90Y-Ibritumomab Tiuxetan in Patients with Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma [NUCLEAR MEDICINE]
Fluorine 18 (18F) FDG PET/CT metabolic data obtained 2 months after radioimmunotherapy (RIT) correlated well with those obtained at 6-month scans and with mid-term clinical evaluation of response to RIT, showing significant difference in maximum standard uptake value (SUVmax) between responders and nonresponders with a better overall survival in patients with a large reduction in SUVmax, as compared with those showing a lesser decrease. (Source: Radiology)
HIV-associated oral plasmablastic lymphoma and role of adherence to highly active antiretroviral therapy
We describe the case of an HIV patient with a lesion in the maxilla that lasted four months. He was diagnosed with PBL and received highly active antiretroviral therapy as well as chemotherapy and local radiotherapy. The lesion regressed after the third cycle of chemotherapy. The patient interrupted antiretroviral treatment and the lesion recurred. The immune reconstitution secondary to the use of antiretroviral therapy seems to participate in the regression of PBL and maintains the remission of the tumour, but it might not be enough to prevent the development of PBL. (Source: International Journal of STD and AIDS)
Systematic review of epidemiological studies on health effects associated with management of municipal solid waste
Conclusions: The studies we have reviewed suffer from many limitations due to poor exposure assessment, ecological level of analysis, and lack of information on relevant confounders. With a moderate level confidence, however, we have derived some effect estimates that could be used for health impact assessment of old landfill and incineration plants. The uncertainties surrounding these numbers should be considered carefully when health effects are estimated. It is clear that future research into the health risks of waste management needs to overcome current limitations. (Source: BioMed Central)
Long-term results of pirarubicin versus doxorubicin in combination chemotherapy for aggressive non-Hodgkin's lymphoma: single center, 15-year experience.
Authors: Zhai L, Guo C, Cao Y, Xiao J, Fu X, Huang J, Huang H, Guan Z, Lin T Pirarubicin is an analog of doxorubicin. Few studies have compared the long-term outcomes of patients receiving pirarubicin-based THP-COP and doxorubicin-based CHOP in the treatment of non-Hodgkin's lymphoma (NHL). We retrospectively compared the efficacy and safety of these two regimens in 459 previously untreated aggressive NHL patients admitted to Sun Yat-Sen University Cancer Center from 1987 to 2003. For initial treatment, 205 patients received the THP-COP regimen, and 254 patients received the CHOP regimen. The patients' characteristics were well balanced. The groups did not differ in the complete remission rate (THP-COP, 57.1% vs. CHOP, 57.0%; P = 0.998) or response rate (THP-COP, 82.9% vs. CHOP, 81.5%;...
Parental Occupational Exposure to Extremely Low Frequency Magnetic Fields and Childhood Cancer: A German Case-Control Study
Extremely low frequency magnetic fields (ELF-MFs) have been classified as possibly carcinogenic to humans by the International Agency for Research on Cancer. The authors investigated, in a population-based case-control study in Germany, if children whose parents were exposed preconceptionally at work to ELF-MFs had an increased risk of developing cancer. Cases aged 0–14 years were ascertained from the German Childhood Cancer Registry. Controls were selected from local resident registration offices. The parental occupational history was recorded in questionnaires and telephone interviews, and preconceptional magnetic field exposure was estimated according to a job-exposure matrix. The analysis included 2,382 controls and 2,049 cases (846 children with acute leukemia, 159 children with...
Identification of non-Hodgkin's lymphoma prognosis signatures using the CTGDR method
Motivation: Although NHL (non-Hodgkin's lymphoma) is the fifth leading cause of cancer incidence and mortality in the USA, it remains poorly understood and is largely incurable. Biomedical studies have shown that genomic variations, measured with SNPs (single nucleotide polymorphisms) in genes, may have independent predictive power for disease-free survival in NHL patients beyond clinical measurements. Results: We apply the CTGDR (clustering threshold gradient directed regularization) method to genetic association studies using SNPs, analyze data from an association study of NHL and identify prognosis signatures to diffuse large B cell lymphoma (DLBCL) and follicular lymphoma (FL), the two most common subtypes of NHL. With the CTGDR method, we are able to account for the joint effects of m...
Pixantrone receives orphan status in EU for treatment of DLBCL
Source: BioSpace Area: News The European Medicines Agency (EMEA) has granted pixantrone orphan drug designation for the treatment of diffuse large B cell lymphoma (DLBCL), which accounts for about 80% of aggressive non-Hodgkin's lymphoma. Pixantrone is a topoisomerase II inhibitor with a molecular structure that differentiates it from the anthracyclines and other related chemotherapy agents. A Marketing Authorisation Application is expected to be filed in the EU in mid-2010. (Source: NeLM - Oncology)
Benzene as a Cause of Lymphoproliferative Disorders.
Authors: Goldstein BD There is a long standing issue concerning the strength of evidence relating benzene to lymphocytic neoplasms. Because benzene is a known cause of human acute myelogenous leukemia there has been little reason for organizations such as the International Agency for Research on Cancer (IARC) or the US National Toxicology Program (NTP) to perform standard hazard identification reviews of benzene as a possible cause of other cancers such as lymphomas. Increased understanding of underlying mechanisms of carcinogenesis, as is reflected in the greater scope given to mechanistic evidence in assigning overall sufficiency of evidence for carcinogenicity by both IARC and NTP, suggests that the evidence supporting benzene as a cause of lymphoma likely has passed the threshold r...
European Medicines Agency Grants Cell Therapeutics Orphan Drug Designation for Pixantrone in Diffuse Large B-Cell Lymphoma (DLBCL)
SEATTLE, Dec. 21 (HSMN NewsFeed) -- Cell Therapeutics, Inc. ("CTI") (Nasdaq and MTA: CTIC) announced today that the European Medicines Agency (EMEA) has granted pixantrone orphan drug designation for the treatment of DLBCL which accounts for ab... Biopharmaceuticals, Oncology, RegulatoryCell Therapeutics, pixantrone, orphan drug designation, non-Hodgkin's lymphoma (Source: HSMN NewsFeed)
What is the function of the protein CD20?
(Journal of Clinical Investigation) Antibodies directed against the protein CD20, which is expressed by immune cells known as B cells, are used to treat B cell non-Hodgkin lymphoma and rheumatoid arthritis. Despite this, the function of CD20 has not been determined. However, researchers have now determined that CD20 has a nonredundant role in generating optimal B cell immune responses by analyzing a patient lacking the protein. (Source: EurekAlert! - Medicine and Health)
Teenage cancer unit: 'like home, but fun'
A new cancer unit for teenagers is a tonic, says Tammy Cohen. (Source: Telegraph Health)
Squamous cell carcinoma of the conjunctiva invading the orbit in a non-Hodgkin lymphoma
Content Type Journal ArticleCategory LettersDOI 10.1007/s10384-009-0733-0Authors Soon-Il Kwon, Hallym University Sacred Heart Hospital Department of Ophthalmology Anyang KoreaYun Suk Chung, Hallym University Sacred Heart Hospital Department of Ophthalmology Anyang KoreaYun-Jeong Kim, Hallym University Sacred Heart Hospital Department of Ophthalmology Anyang Korea Journal Japanese Journal of OphthalmologyOnline ISSN 1613-2246Print ISSN 0021-5155 Journal Volume Volume 53 Journal Issue Volume 53, Number 6 / November, 2009 (Source: Japanese Journal of Ophthalmology)
Patients' Supportive Care Needs Beyond the End of Cancer Treatment: A Prospective, Longitudinal Survey [Palliative and Supportive Care]
Conclusion Most patients do not express unmet needs for supportive care after treatment. Thirty percent reported more than five moderate or severe unmet needs at both assessments. Unmet needs were predicted by hormone treatment, negative mood, and experiencing a significant event. Our results suggest that there is a proportion of survivors with unmet needs who might benefit from the targeted application of psychosocial resources. (Source: Journal of Clinical Oncology)
Immunochemotherapy and Autologous Stem-Cell Transplantation for Untreated Patients With Mantle-Cell Lymphoma: CALGB 59909 [Hematologic Malignancies]
Conclusion The Cancer and Leukemia Group B 59909 regimen is feasible, safe, and effective in patients with newly diagnosed MCL. The incorporation of rituximab with aggressive chemotherapy and ASCT may be responsible for the encouraging outcomes demonstrated in this study, which produced results comparable to similar treatment regimens. (Source: Journal of Clinical Oncology)
Cell Therapeutics Announces FDA's Oncologic Drugs Advisory Committee to Review Pixantrone for the Treatment of Relapsed/Refractory Aggressive Non-Hodgkin's Lymphoma, February 10, 2010
SEATTLE, Dec. 17 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (CTI) (Nasdaq and MTA: CTIC) announced today that on February 10, 2010 the U.S. Food and Drug Administration's Oncologic Drugs Advisory Committee (ODAC) will review the New Drug... (Source: Drugs.com - New Drug Applications)
Cell Therapeutics Announces FDA's Oncologic Drugs Advisory Committee to Review Pixantrone for the Treatment of Relapsed/Refractory Aggressive Non-Hodgkin's Lymphoma, February 10, 2010
SEATTLE, Dec. 17 (HSMN NewsFeed) -- Cell Therapeutics, Inc. (CTI) (Nasdaq and MTA: CTIC) announced today that on February 10, 2010 the U.S. Food and Drug Administration's Oncologic Drugs Advisory Committee (ODAC) will review the New Drug Application (NDA... Biopharmaceuticals, OncologyCell Therapeutics, pixantrone, non-Hodgkin's lymphoma (Source: HSMN NewsFeed)
[Current therapeutic options in Sjögren's syndrome.]
[Current therapeutic options in Sjögren's syndrome.] Z Rheumatol. 2009 Dec 17; Authors: Hansen A, Dörner T Sjögren's syndrome is a systemic inflammatory-rheumatic disorder of hitherto unknown origin and, hence, adequate therapy options are not available in most cases. Treatment of sicca symptoms in Sjögren's patients is primarily symptomatic. Glucocorticoids, NSAIDs and/or immunosuppressive drugs may be used for the treatment of extraglandular manifestations or complications. Although there have been few clinical studies to date, new insights into the pathogenesis of this disorder may permit novel therapeutic strategies. Targeting B-cell candidates as a new therapeutic option in this entity has shown promising results. B-cell-depletion using Rituximab has be...
Pattern of declining hemoglobin concentration before cancer diagnosis
In conclusion, in this study, we have demonstrated that the pattern of declining hemoglobin concentration before cancer diagnosis varies considerably between malignancies without being a suitable screening tool for any of them. For some malignancies, however, the long duration of hemoglobin decline before clinical diagnosis suggests a substantial lead-time with systemic effects, during which earlier diagnosis should be achievable by emerging diagnostic tools. (Source: International Journal of Cancer)
Immunohistochemical and other prognostic factors in B cell non Hodgkin lymphoma patients, Kampala, Uganda
Conclusions: Activated GCB Diffuse large B cell lymphoma had a better prognosis than the others. For Burkitt lymphoma, not receiving chemotherapy carried a poor prognosis. Availability of chemotherapy in this resource limited setting is critical for survival of lymphoma patients. (Source: BMC Clinical Pathology - Latest articles)
Plerixafor for Stem Cell Mobilization in Patients with Non-Hodgkin's Lymphoma and Multiple Myeloma (January) (CE).
CONCLUSIONS: Clinical trials have demonstrated that the addition of plerixafor to G-CSF was beneficial for HSC mobilization to peripheral blood for collection and subsequent transplantation in patients with NHL or multiple myeloma. Further studies should assess the benefit of the additive use of plerixafor on clinical outcomes. PMID: 20009003 [PubMed - as supplied by publisher] (Source: The Annals of Pharmacotherapy)
Molecular targeted therapies for diffuse large B-cell lymphoma based on apoptosis profiles
Diffuse large B-cell lymphoma (DLBCL) is the most common type of adult non-Hodgkin lymphoma and is treated with chemotherapy in combination with rituximab. Despite this aggressive therapy, the disease is fatal in 30-40% of patients. Inhibition of the apoptosis signalling pathways is strongly related to response to chemotherapy and eventual clinical outcome. In order to survive, lymphoma cells depend on disruption of the apoptosis pathway by mutations in apoptosis inducing genes or by continuous expression of anti-apoptotic proteins. The development of molecules targeting these apoptosis inhibitors provides a very promising opportunity to specifically target tumour cells without toxicity to non-malignant cells in DLBCL patients. Sensitivity for most of these antagonists can be predicted bas...
SAR3419 Phase I Study Results In Non-Hodgkin's Lymphoma At ASH
ImmunoGen, Inc. (Nasdaq: IMGN), a biopharmaceutical company that develops targeted anticancer therapeutics, announced the presentation of encouraging initial clinical findings with SAR3419 at the American Society of Hematology (ASH) 51st Annual Meeting and Exposition. Among the findings reported were responses to SAR3419 - administered as a single agent - among patients with B-cell non-Hodgkin's lymphoma that is refractory to treatment with rituximab (Rituxan®)... (Source: Health News from Medical News Today)
SAR3419 Phase I Study Results In Non-Hodgkin's Lymphoma At ASH
ImmunoGen, Inc. (Nasdaq: IMGN), a biopharmaceutical company that develops targeted anticancer therapeutics, announced the presentation of encouraging initial clinical findings with SAR3419 at the American Society of Hematology (ASH) 51st Annual Meeting and Exposition... (Source: Cancer / Oncology News From Medical News Today)
SAR3419 Phase I Study Results In Non-Hodgkin's Lymphoma At ASH
ImmunoGen, Inc. (Nasdaq: IMGN), a biopharmaceutical company that develops targeted anticancer therapeutics, announced the presentation of encouraging initial clinical findings with SAR3419 at the American Society of Hematology (ASH) 51st Annual Meeting and Exposition... (Source: Lymphoma / Leukemia News From Medical News Today)
Secondary osteosarcoma arising after treatment for childhood hematologic malignancies.
We report two cases of secondary osteosarcoma arising after treatment for childhood hematologic malignancies (non-Hodgkin's lymphoma and lymphoblastic leukemia). A 10-year-old boy, at the age of 3, was diagnosed with non-Hodgkin's lymphoma. He received chemotherapy, radiation, and bone-marrow transplantation and then was in complete remission. At 6 years, he complained of increasing pain of the right thigh and was diagnosed with osteoblastic osteosarcoma. A 26-year-old man, at the age of 6, was diagnosed as having acute lymphoblastic leukemia (ALL). He received chemotherapy, radiation, and peripheral blood stem cell transplantation (PBSCT). At 11 years after PBSCT, he visited with the complaint of left lumbar swelling. He was diagnosed with chondroblastic osteosarcoma. In both cases alkali...
Blood cancers: New research demonstrates advances in optimizing treatments and quality of life
New research explores optimal induction therapies for managing multiple myeloma, the importance of advance care planning for improved quality of life, and a potential new first-line therapy for patients with non-Hodgkin lymphoma. (Source: ScienceDaily Headlines)
Long-Term BEXXAR(R) Data Demonstrate Overall Survival
GlaxoSmithKline announced updated long-term survival data from two Phase II studies of BEXXAR® (tositumomab and iodine I-131 tositumomab) used in either patients with previously untreated cancer of the immune system (follicular lymphoma) or in patients with cancer of the lymphocytes (non-Hodgkin's lymphoma, NHL) that no longer responded to rituximab. The first study demonstrated that, among 76 patients with previously untreated follicular lymphoma, the 10-year overall survival rate was 83% and the 10-year progression-free survival rate was 38%... (Source: Health News from Medical News Today)
Long-Term BEXXAR(R) Data Demonstrate Overall Survival
GlaxoSmithKline announced updated long-term survival data from two Phase II studies of BEXXAR® (tositumomab and iodine I-131 tositumomab) used in either patients with previously untreated cancer of the immune system (follicular lymphoma) or in patients with cancer of the lymphocytes (non-Hodgkin's lymphoma, NHL) that no longer responded to rituximab... (Source: Lymphoma / Leukemia News From Medical News Today)
HLA DR-DQ combination associated with the increased risk of developing human HCV positive non-Hodgkin's lymphoma is related to the type II mixed cryoglobulinemia
This investigation was focused on the contribution of individual human leukocyte antigen (HLA)-DR and -DQ alleles to the human hepatitis C virus (HCV)+ non-Hodgkin's lymphoma (NHL), with and without mixed cryoglobulinemia (MC), to study whether individual HLA class II alleles are expressed preferentially or equally in human HCV-specific NHL. For this purpose, peripheral blood mononuclear cells were obtained from two groups of patients with HCV+ NHL and with or without MC (70 and 71 cases, respectively), and from 4575 blood donors. Eighty-three subjects with HCV infection only, and 118 patients with MC, only without lymphoma, were added as additional control groups. Individual HLA-DR and -DQ alleles were determined using high-resolution sequence-based typing and then data were collected by ...
Calistoga Pharmaceuticals' CAL-101, an Oral Delta Isoform-Selective PI3 Kinase Inhibitor, Demonstrates Clinical Benefit in Patients with Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma, Mantle Cell Lymphoma and Chronic Lymphocytic Leukemia
Interim Results From Phase 1 Study Demonstrate Single Agent Activity   Preclinical Data Support Induction of Cell Death and Ability to Inhibit Signaling Pathways Associated with Cancer Cell Dependence on the Tumor... (Source: Drugs.com - Clinical Trials)
The Addition of VELCADE (Bortezomib) for Injection to Novel Combination Delivers Promising Results in Patients with Non-Hodgkin's Lymphoma
-- VELCADE, rituximab and bendamustine deliver high complete remission rate to patients with relapsed/refractory non-Hodgkin's lymphoma -- NEW ORLEANS--(BUSINESS WIRE)--Dec 8, 2009 - Millennium: The Takeda Oncology Company today reported data from... (Source: Drugs.com - Clinical Trials)
Long-Term Bexxar Data Demonstrate Overall Survival
Long-term Results in both First-line and Refractory Settings Seen in Patients with Non-Hodgkin's Lymphoma PHILADELPHIA, Dec. 8 /PRNewswire/ -- GlaxoSmithKline announced today updated long-term survival data from two Phase II studies of BEXXAR®... (Source: Drugs.com - Clinical Trials)
Data From Phase 1 Study Confirm High Response Rate Of Micromet's Blinatumomab In Patients With Non Hodgkins Lymphoma
Micromet, Inc. (Nasdaq: MITI), a biopharmaceutical company developing novel, proprietary antibodies for the treatment of cancer, inflammation and autoimmune diseases, announced the publication of a poster(1) with new data from its ongoing phase 1 clinical trial of its product candidate blinatumomab in patients with non-Hodgkin's lymphoma (NHL) at the 51ST Annual Meeting of the American Society of Hematology (ASH) in New Orleans, Louisiana... (Source: Health News from Medical News Today)
Data From Phase 1 Study Confirm High Response Rate Of Micromet's Blinatumomab In Patients With Non Hodgkins Lymphoma
Micromet, Inc... (Source: Lymphoma / Leukemia News From Medical News Today)
Peripheral Blood Stem Cell Mobilization Tactics (January).
CONCLUSIONS: The optimal mobilization strategy is still unknown; however, colony-stimulating factors remain the most commonly used mobilization agents. Currently, chemotherapy or plerixafor in combination with G-CSF is a reasonable option in heavily pretreated and hard-to-mobilize patients with non-Hodgkin's lymphoma and multiple myeloma. PMID: 19996324 [PubMed - as supplied by publisher] (Source: The Annals of Pharmacotherapy)
Immunomedics Announces Preclinical Results of Milatuzumab in B-Cell Malignancies
NEW ORLEANS, Dec. 7, 2009 (GLOBE NEWSWIRE) -- Immunomedics, Inc. (Nasdaq:IMMU), a biopharmaceutical company focused on developing monoclonal antibodies to treat cancer and other serious diseases, today at the 51st annual meeting of the American Society of Hematology announced results from 3 preclinical studies aimed at understanding the mechanism of action of its proprietary humanized anti-CD74 antibody, milatuzumab, which is currently in clinical development for multiple myeloma (MM), non-Hodgkin's lymphoma (NHL) and chronic lymphocytic leukemia (CLL). (Source: Medical News (via PRIMEZONE))
Vitamin D Levels Associated With Survival In Lymphoma Patients Discovered By Mayo Clinic And Collaborators
A new study has found that the amount of vitamin D (http://www.mayoclinic.org/news2008-mchi/4904.html) in patients being treated for diffuse large B-cell lymphoma (http://www.mayoclinic.org/non-hodgkins-lymphoma/) was strongly associated with cancer progression and overall survival. The results were presented at the annual meeting of the American Society of Hematology (http://www.hematology.org/) in New Orleans. "These are some of the strongest findings yet between vitamin D and cancer outcome," says the study's lead investigator, Matthew Drake, M.D., Ph.D., (http://www.mayoclinic... (Source: Health News from Medical News Today)
Vitamin D Levels Associated With Survival In Lymphoma Patients Discovered By Mayo Clinic And Collaborators
A new study has found that the amount of vitamin D (http://www.mayoclinic.org/news2008-mchi/4904.html) in patients being treated for diffuse large B-cell lymphoma (http://www.mayoclinic.org/non-hodgkins-lymphoma/) was strongly associated with cancer progression and overall survival. The results were presented at the annual meeting of the American Society of Hematology (http://www.hematology... (Source: Lymphoma / Leukemia News From Medical News Today)
Vitamin D May Boost Lymphoma Survival
Healthy levels of vitamin D may help patients with a certain type of non-Hodgkin's lymphoma live longer, a study shows. (Source: WebMD Health)

Powered by FirstRSS Plugin